Cadrenal Therapeutics, Inc.
corporate_fare Company Profile
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for CVKD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CVKD spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Cadrenal 10-Q: Going Concern Reiterated, Cash Runs to Q1 2027, Defective ATM Sales Ratified
- Cadrenal Launches Formal Strategic Review, Hires Tungsten Advisors
- Cadrenal Secures FDA Alignment on Phase 3 Endpoint for CAD-1005 in HIT
- FDA Aligns on Phase 3 Endpoint for CAD-1005 in HIT, Clearing Path to Registration
- Cadrenal Reports Q2 Loss, $4.2M Cash Runway to Q1 2027, Launches Partnering Process
Financial Snapshot
Short Interest & Short Volume
3.48 days to coverFINRA reported short interest of 230,655 shares in CVKD as of the October 30, 2026 settlement, a 18.0% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 51.1% of CVKD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for CVKD, detected from its recent SEC filings · based on capital-structure filings through 2026-07-20.
Resale Registration of 2.94M Shares · Potential $6M in Additional Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →